The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
The global CGT CDMO market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for CGT CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CGT CDMO.
Report Scope
The CGT CDMO market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global CGT CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CGT CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
WuXi AppTec
OBiO
GenScript
Porton
Lonza
Pharmaron
Catalent
Thermo Fisher
Oxford Biomedica (OXB)
Asymchem
Rentschler Biopharma
Novartis
Segment by Type
Immune Cells
Stem Cells
Viral Vectors
Plasmid DNA
Segment by Application
Pharmaceutical and Biotechnology Companies
Research and Academic Institutions
Hospital
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CGT CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global CGT CDMO market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for CGT CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CGT CDMO.
Report Scope
The CGT CDMO market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global CGT CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CGT CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
WuXi AppTec
OBiO
GenScript
Porton
Lonza
Pharmaron
Catalent
Thermo Fisher
Oxford Biomedica (OXB)
Asymchem
Rentschler Biopharma
Novartis
Segment by Type
Immune Cells
Stem Cells
Viral Vectors
Plasmid DNA
Segment by Application
Pharmaceutical and Biotechnology Companies
Research and Academic Institutions
Hospital
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CGT CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CGT CDMO Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Immune Cells
1.2.3 Stem Cells
1.2.4 Viral Vectors
1.2.5 Plasmid DNA
1.3 Market by Application
1.3.1 Global CGT CDMO Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Pharmaceutical and Biotechnology Companies
1.3.3 Research and Academic Institutions
1.3.4 Hospital
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global CGT CDMO Market Perspective (2019-2030)
2.2 CGT CDMO Growth Trends by Region
2.2.1 Global CGT CDMO Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 CGT CDMO Historic Market Size by Region (2019-2024)
2.2.3 CGT CDMO Forecasted Market Size by Region (2025-2030)
2.3 CGT CDMO Market Dynamics
2.3.1 CGT CDMO Industry Trends
2.3.2 CGT CDMO Market Drivers
2.3.3 CGT CDMO Market Challenges
2.3.4 CGT CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top CGT CDMO Players by Revenue
3.1.1 Global Top CGT CDMO Players by Revenue (2019-2024)
3.1.2 Global CGT CDMO Revenue Market Share by Players (2019-2024)
3.2 Global CGT CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by CGT CDMO Revenue
3.4 Global CGT CDMO Market Concentration Ratio
3.4.1 Global CGT CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CGT CDMO Revenue in 2023
3.5 CGT CDMO Key Players Head office and Area Served
3.6 Key Players CGT CDMO Product Solution and Service
3.7 Date of Enter into CGT CDMO Market
3.8 Mergers & Acquisitions, Expansion Plans
4 CGT CDMO Breakdown Data by Type
4.1 Global CGT CDMO Historic Market Size by Type (2019-2024)
4.2 Global CGT CDMO Forecasted Market Size by Type (2025-2030)
5 CGT CDMO Breakdown Data by Application
5.1 Global CGT CDMO Historic Market Size by Application (2019-2024)
5.2 Global CGT CDMO Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America CGT CDMO Market Size (2019-2030)
6.2 North America CGT CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America CGT CDMO Market Size by Country (2019-2024)
6.4 North America CGT CDMO Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CGT CDMO Market Size (2019-2030)
7.2 Europe CGT CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe CGT CDMO Market Size by Country (2019-2024)
7.4 Europe CGT CDMO Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CGT CDMO Market Size (2019-2030)
8.2 Asia-Pacific CGT CDMO Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific CGT CDMO Market Size by Region (2019-2024)
8.4 Asia-Pacific CGT CDMO Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America CGT CDMO Market Size (2019-2030)
9.2 Latin America CGT CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America CGT CDMO Market Size by Country (2019-2024)
9.4 Latin America CGT CDMO Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CGT CDMO Market Size (2019-2030)
10.2 Middle East & Africa CGT CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa CGT CDMO Market Size by Country (2019-2024)
10.4 Middle East & Africa CGT CDMO Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 WuXi AppTec
11.1.1 WuXi AppTec Company Detail
11.1.2 WuXi AppTec Business Overview
11.1.3 WuXi AppTec CGT CDMO Introduction
11.1.4 WuXi AppTec Revenue in CGT CDMO Business (2019-2024)
11.1.5 WuXi AppTec Recent Development
11.2 OBiO
11.2.1 OBiO Company Detail
11.2.2 OBiO Business Overview
11.2.3 OBiO CGT CDMO Introduction
11.2.4 OBiO Revenue in CGT CDMO Business (2019-2024)
11.2.5 OBiO Recent Development
11.3 GenScript
11.3.1 GenScript Company Detail
11.3.2 GenScript Business Overview
11.3.3 GenScript CGT CDMO Introduction
11.3.4 GenScript Revenue in CGT CDMO Business (2019-2024)
11.3.5 GenScript Recent Development
11.4 Porton
11.4.1 Porton Company Detail
11.4.2 Porton Business Overview
11.4.3 Porton CGT CDMO Introduction
11.4.4 Porton Revenue in CGT CDMO Business (2019-2024)
11.4.5 Porton Recent Development
11.5 Lonza
11.5.1 Lonza Company Detail
11.5.2 Lonza Business Overview
11.5.3 Lonza CGT CDMO Introduction
11.5.4 Lonza Revenue in CGT CDMO Business (2019-2024)
11.5.5 Lonza Recent Development
11.6 Pharmaron
11.6.1 Pharmaron Company Detail
11.6.2 Pharmaron Business Overview
11.6.3 Pharmaron CGT CDMO Introduction
11.6.4 Pharmaron Revenue in CGT CDMO Business (2019-2024)
11.6.5 Pharmaron Recent Development
11.7 Catalent
11.7.1 Catalent Company Detail
11.7.2 Catalent Business Overview
11.7.3 Catalent CGT CDMO Introduction
11.7.4 Catalent Revenue in CGT CDMO Business (2019-2024)
11.7.5 Catalent Recent Development
11.8 Thermo Fisher
11.8.1 Thermo Fisher Company Detail
11.8.2 Thermo Fisher Business Overview
11.8.3 Thermo Fisher CGT CDMO Introduction
11.8.4 Thermo Fisher Revenue in CGT CDMO Business (2019-2024)
11.8.5 Thermo Fisher Recent Development
11.9 Oxford Biomedica (OXB)
11.9.1 Oxford Biomedica (OXB) Company Detail
11.9.2 Oxford Biomedica (OXB) Business Overview
11.9.3 Oxford Biomedica (OXB) CGT CDMO Introduction
11.9.4 Oxford Biomedica (OXB) Revenue in CGT CDMO Business (2019-2024)
11.9.5 Oxford Biomedica (OXB) Recent Development
11.10 Asymchem
11.10.1 Asymchem Company Detail
11.10.2 Asymchem Business Overview
11.10.3 Asymchem CGT CDMO Introduction
11.10.4 Asymchem Revenue in CGT CDMO Business (2019-2024)
11.10.5 Asymchem Recent Development
11.11 Rentschler Biopharma
11.11.1 Rentschler Biopharma Company Detail
11.11.2 Rentschler Biopharma Business Overview
11.11.3 Rentschler Biopharma CGT CDMO Introduction
11.11.4 Rentschler Biopharma Revenue in CGT CDMO Business (2019-2024)
11.11.5 Rentschler Biopharma Recent Development
11.12 Novartis
11.12.1 Novartis Company Detail
11.12.2 Novartis Business Overview
11.12.3 Novartis CGT CDMO Introduction
11.12.4 Novartis Revenue in CGT CDMO Business (2019-2024)
11.12.5 Novartis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global CGT CDMO Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Immune Cells
Table 3. Key Players of Stem Cells
Table 4. Key Players of Viral Vectors
Table 5. Key Players of Plasmid DNA
Table 6. Global CGT CDMO Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global CGT CDMO Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global CGT CDMO Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global CGT CDMO Market Share by Region (2019-2024)
Table 10. Global CGT CDMO Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global CGT CDMO Market Share by Region (2025-2030)
Table 12. CGT CDMO Market Trends
Table 13. CGT CDMO Market Drivers
Table 14. CGT CDMO Market Challenges
Table 15. CGT CDMO Market Restraints
Table 16. Global CGT CDMO Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global CGT CDMO Market Share by Players (2019-2024)
Table 18. Global Top CGT CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CGT CDMO as of 2023)
Table 19. Ranking of Global Top CGT CDMO Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by CGT CDMO Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players CGT CDMO Product Solution and Service
Table 23. Date of Enter into CGT CDMO Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global CGT CDMO Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global CGT CDMO Revenue Market Share by Type (2019-2024)
Table 27. Global CGT CDMO Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global CGT CDMO Revenue Market Share by Type (2025-2030)
Table 29. Global CGT CDMO Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global CGT CDMO Revenue Market Share by Application (2019-2024)
Table 31. Global CGT CDMO Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global CGT CDMO Revenue Market Share by Application (2025-2030)
Table 33. North America CGT CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America CGT CDMO Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America CGT CDMO Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe CGT CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe CGT CDMO Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe CGT CDMO Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific CGT CDMO Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific CGT CDMO Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific CGT CDMO Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America CGT CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America CGT CDMO Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America CGT CDMO Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa CGT CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa CGT CDMO Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa CGT CDMO Market Size by Country (2025-2030) & (US$ Million)
Table 48. WuXi AppTec Company Detail
Table 49. WuXi AppTec Business Overview
Table 50. WuXi AppTec CGT CDMO Product
Table 51. WuXi AppTec Revenue in CGT CDMO Business (2019-2024) & (US$ Million)
Table 52. WuXi AppTec Recent Development
Table 53. OBiO Company Detail
Table 54. OBiO Business Overview
Table 55. OBiO CGT CDMO Product
Table 56. OBiO Revenue in CGT CDMO Business (2019-2024) & (US$ Million)
Table 57. OBiO Recent Development
Table 58. GenScript Company Detail
Table 59. GenScript Business Overview
Table 60. GenScript CGT CDMO Product
Table 61. GenScript Revenue in CGT CDMO Business (2019-2024) & (US$ Million)
Table 62. GenScript Recent Development
Table 63. Porton Company Detail
Table 64. Porton Business Overview
Table 65. Porton CGT CDMO Product
Table 66. Porton Revenue in CGT CDMO Business (2019-2024) & (US$ Million)
Table 67. Porton Recent Development
Table 68. Lonza Company Detail
Table 69. Lonza Business Overview
Table 70. Lonza CGT CDMO Product
Table 71. Lonza Revenue in CGT CDMO Business (2019-2024) & (US$ Million)
Table 72. Lonza Recent Development
Table 73. Pharmaron Company Detail
Table 74. Pharmaron Business Overview
Table 75. Pharmaron CGT CDMO Product
Table 76. Pharmaron Revenue in CGT CDMO Business (2019-2024) & (US$ Million)
Table 77. Pharmaron Recent Development
Table 78. Catalent Company Detail
Table 79. Catalent Business Overview
Table 80. Catalent CGT CDMO Product
Table 81. Catalent Revenue in CGT CDMO Business (2019-2024) & (US$ Million)
Table 82. Catalent Recent Development
Table 83. Thermo Fisher Company Detail
Table 84. Thermo Fisher Business Overview
Table 85. Thermo Fisher CGT CDMO Product
Table 86. Thermo Fisher Revenue in CGT CDMO Business (2019-2024) & (US$ Million)
Table 87. Thermo Fisher Recent Development
Table 88. Oxford Biomedica (OXB) Company Detail
Table 89. Oxford Biomedica (OXB) Business Overview
Table 90. Oxford Biomedica (OXB) CGT CDMO Product
Table 91. Oxford Biomedica (OXB) Revenue in CGT CDMO Business (2019-2024) & (US$ Million)
Table 92. Oxford Biomedica (OXB) Recent Development
Table 93. Asymchem Company Detail
Table 94. Asymchem Business Overview
Table 95. Asymchem CGT CDMO Product
Table 96. Asymchem Revenue in CGT CDMO Business (2019-2024) & (US$ Million)
Table 97. Asymchem Recent Development
Table 98. Rentschler Biopharma Company Detail
Table 99. Rentschler Biopharma Business Overview
Table 100. Rentschler Biopharma CGT CDMO Product
Table 101. Rentschler Biopharma Revenue in CGT CDMO Business (2019-2024) & (US$ Million)
Table 102. Rentschler Biopharma Recent Development
Table 103. Novartis Company Detail
Table 104. Novartis Business Overview
Table 105. Novartis CGT CDMO Product
Table 106. Novartis Revenue in CGT CDMO Business (2019-2024) & (US$ Million)
Table 107. Novartis Recent Development
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
List of Figures
Figure 1. Global CGT CDMO Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global CGT CDMO Market Share by Type: 2023 VS 2030
Figure 3. Immune Cells Features
Figure 4. Stem Cells Features
Figure 5. Viral Vectors Features
Figure 6. Plasmid DNA Features
Figure 7. Global CGT CDMO Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global CGT CDMO Market Share by Application: 2023 VS 2030
Figure 9. Pharmaceutical and Biotechnology Companies Case Studies
Figure 10. Research and Academic Institutions Case Studies
Figure 11. Hospital Case Studies
Figure 12. Others Case Studies
Figure 13. CGT CDMO Report Years Considered
Figure 14. Global CGT CDMO Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 15. Global CGT CDMO Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global CGT CDMO Market Share by Region: 2023 VS 2030
Figure 17. Global CGT CDMO Market Share by Players in 2023
Figure 18. Global Top CGT CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CGT CDMO as of 2023)
Figure 19. The Top 10 and 5 Players Market Share by CGT CDMO Revenue in 2023
Figure 20. North America CGT CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. North America CGT CDMO Market Share by Country (2019-2030)
Figure 22. United States CGT CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Canada CGT CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe CGT CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe CGT CDMO Market Share by Country (2019-2030)
Figure 26. Germany CGT CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. France CGT CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. U.K. CGT CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Italy CGT CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Russia CGT CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Nordic Countries CGT CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific CGT CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific CGT CDMO Market Share by Region (2019-2030)
Figure 34. China CGT CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Japan CGT CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. South Korea CGT CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Southeast Asia CGT CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. India CGT CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Australia CGT CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America CGT CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America CGT CDMO Market Share by Country (2019-2030)
Figure 42. Mexico CGT CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Brazil CGT CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa CGT CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa CGT CDMO Market Share by Country (2019-2030)
Figure 46. Turkey CGT CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Saudi Arabia CGT CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. WuXi AppTec Revenue Growth Rate in CGT CDMO Business (2019-2024)
Figure 49. OBiO Revenue Growth Rate in CGT CDMO Business (2019-2024)
Figure 50. GenScript Revenue Growth Rate in CGT CDMO Business (2019-2024)
Figure 51. Porton Revenue Growth Rate in CGT CDMO Business (2019-2024)
Figure 52. Lonza Revenue Growth Rate in CGT CDMO Business (2019-2024)
Figure 53. Pharmaron Revenue Growth Rate in CGT CDMO Business (2019-2024)
Figure 54. Catalent Revenue Growth Rate in CGT CDMO Business (2019-2024)
Figure 55. Thermo Fisher Revenue Growth Rate in CGT CDMO Business (2019-2024)
Figure 56. Oxford Biomedica (OXB) Revenue Growth Rate in CGT CDMO Business (2019-2024)
Figure 57. Asymchem Revenue Growth Rate in CGT CDMO Business (2019-2024)
Figure 58. Rentschler Biopharma Revenue Growth Rate in CGT CDMO Business (2019-2024)
Figure 59. Novartis Revenue Growth Rate in CGT CDMO Business (2019-2024)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
